Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.

Cummings JL, Nadel A, Masterman D, Cyrus PA.

J Geriatr Psychiatry Neurol. 2001 Summer;14(2):101-8.

PMID:
11419566
2.

Metrifonate for Alzheimer's disease.

López-Arrieta JM, Schneider L.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003155. Review.

PMID:
16625573
3.

Neuropsychiatric assessment of Alzheimer's disease and related dementias.

Cummings JL, McPherson S.

Aging (Milano). 2001 Jun;13(3):240-6. Review.

PMID:
11444257
4.

Evaluating response to metrifonate.

Tariot PN.

J Clin Psychiatry. 1998;59 Suppl 9:33-7. Review.

PMID:
9720485
5.
7.

Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.

Levy ML, Cummings JL, Kahn-Rose R.

Gerontology. 1999;45 Suppl 1:15-22. Review.

PMID:
9876214
8.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ.

Consult Pharm. 2007 Sep;22(9):754-62. Review.

PMID:
18198970
9.

Metrifonate: a new agent for the treatment of Alzheimer's disease.

Williams BR.

Am J Health Syst Pharm. 1999 Mar 1;56(5):427-32. Review.

PMID:
10096702
10.
11.

Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease.

Wynn ZJ, Cummings JL.

Dement Geriatr Cogn Disord. 2004;17(1-2):100-8. Epub 2003 Oct 15. Review.

PMID:
14564129
12.

Metrifonate: overview of safety and efficacy.

Cummings JL.

Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):43-6; discussion 79-82. Review.

PMID:
9543464
13.

The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.

Cummings JL, Back C.

Am J Geriatr Psychiatry. 1998 Spring;6(2 Suppl 1):S64-78. Review.

PMID:
9581223
14.

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Cummings JL.

Neurology. 1997 May;48(5 Suppl 6):S10-6. Review.

PMID:
9153155
15.

The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.

Schmidt BH, Heinig R.

Dement Geriatr Cogn Disord. 1998;9 Suppl 2:15-9. Review.

PMID:
9718230
16.

Alzheimer's disease: clinical treatment options.

Reichman WE.

Am J Manag Care. 2000 Dec;6(22 Suppl):S1125-32; discussion S1133-8. Review.

17.

Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.

Raskind MA.

J Clin Psychiatry. 1998;59 Suppl 9:28-32. Review.

PMID:
9720484
18.

Metrifonate: update on a new antidementia agent.

Ringman JM, Cummings JL.

J Clin Psychiatry. 1999 Nov;60(11):776-82. Review.

PMID:
10584768
19.

[Biological therapies of behavioral and psychological symptoms of dementia: update and prospects].

Gallarda T, Olie JP.

Encephale. 2000 May-Jun;26(3):72-80. Review. French.

PMID:
10951909
20.

Preclinical pharmacology of metrifonate.

Jann MW.

Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):55-67; discussion 79-82. Review.

PMID:
9543466
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk